Noema Pharma raises $112M Series B to advance CNS disorder pipeline with Roche candidates
Swiss biotech Noema Pharma jumpstarted back in 2020 with a $60 million Series A financing round. Today, it’s wrapping up its Series B round with another $112 million to develop its pipeline of molecules focused on central nervous system disorders.
Noema started out with four clinical stage assets in-licensed from Roche. The company says it will use this new round of financing to push forward its lead candidate basimglurant (NOE-101), an mGluR5 inhibitor which is currently being evaluated in Phase IIb clinical trials for severe pain in trigeminal neuralgia and seizures in tuberous sclerosis complex.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.